Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 2Phase 2 1Phase 1/2 1

Status

Completed 4

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4Tumor-Agnostic 1

Conditions

Melanoma 4Neoplasms 2Neoplasm Metastasis 1

Interventions

Nivolumab 168Ipilimumab 152pembrolizumab 143Cyclophosphamide 126Interleukin-2 70aldesleukin 69fludarabine phosphate 68Radiotherapy 67Biopsy 53Temozolomide 48Blood Specimen Collection 45Peripheral Blood Stem Cell Transplantation 44fludarabine 43Radiosurgery 40trametinib 38Vemurafenib 36dabrafenib 33sargramostim 32Bevacizumab 31Aminolevulinic Acid 31Magnetic Resonance Spectroscopy 30Mycophenolic Acid 29Specimen Handling 28Whole-Body Irradiation 27Photochemotherapy 26Imiquimod 26CTLA-4 Antigen 26Busulfan 26Tacrolimus 25Surveys and Questionnaires 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × resiquimod × Dermatologic × Clear all
NCT02126579 2024-02-28

MEL60

University of Virginia

Phase 1/2 Completed
50 enrolled 13 charts
Dermatologic

Melanoma, Neoplasms

NCT00960752 2021-08-13

Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist

M.D. Anderson Cancer Center

Phase 2 Completed
47 enrolled 9 charts
Dermatologic

Melanoma, Neoplasm Metastasis, Neoplasms

NCT01748747 2018-10-09

Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery

Mayo Clinic

Phase EARLY_PHASE1 Completed
30 enrolled
Dermatologic

Melanoma

NCT00470379 2014-10-31

Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery

Mayo Clinic

Phase EARLY_PHASE1 Completed
30 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡